Oncology
Refine Search
Biotechnology
Research news last week included US biotech releasing early data for its FT819 in the treatment of systemic lupus erythematosus (SLE), which sent the firm’s shares leaping as much as 70%. Also, Netherlands-based NewAmsterdam Pharma announced positive data on its obicetrapib and ezetimibe combination in cardiovascular disease. On the regulatory front, Dutch firm argenX and China’s Zai Lab gained approval from the Chinese medicines regulator for their Vyvgart Hytrulo in chronic inflammatory demyelinating polyneuropathy (CIDP) care. Meantime, USA-based Kura Oncology signed a collaboration with Japan’s Kyowa Kirin on the development of ziftomenib for myeloid leukemia (ALS). 24 November 2024
Biotechnology
Japanese drugmaker Takeda has launched Fruzaqla (fruquintinib) in its home country. 22 November 2024
Biotechnology
Chinese biopharma CStone Pharmaceuticals has announced a strategic commercial collaboration with Pharmalink Store, a prominent pharmaceutical company based in the United Arab Emirates (UAE). 22 November 2024
Biotechnology
Privately-held US biotech Alloy Therapeutics has announced a strategic collaboration and license agreement with Takeda Pharmaceutical. 21 November 2024
Pharmaceutical
Japanese drugmaker Eisai has announced that the amyotrophic lateral sclerosis (ALS) treatment Rozebalamin for Injection (mecobalamin) has been launched in Japan as a treatment for slowing progression of functional impairment in amyotrophic lateral sclerosis. 21 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has granted accelerated approval of Ziihera (zanidatamab-hrii) 50mg/mL for injection for intravenous use, say the drug’s developer, Jazz Pharmaceuticals. 21 November 2024
Biotechnology
San Diego-based Kura Oncology and Japan’s Kyowa Kirin have entered into a global strategic collaboration to develop and commercialize ziftomenib. 21 November 2024
Pharmaceutical
Shanghai-based Leading Tac Pharmaceutical has announced the successful completion of a series A financing round, raising over 100 million yuan ($14 million). 21 November 2024
Biotechnology
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
Biotechnology
Bioplatform company builder Flagship Pioneering has announced its companies Ampersand Biomedicines and Montai Therapeutics have entered into agreements to identify targeted molecules that could potentially be further developed as treatments for obesity and lung cancer. 20 November 2024
Pharmaceutical
Ascentage Pharma will see its investigational BCL-2 selective inhibitor, lisaftoclax, assessed under China’s Priority Review scheme. 20 November 2024
Biosimilars
Sweden-based Xbrane Biopharma and Intas Pharmaceuticals have announced an exclusive global licensing and co-development agreement for the former company’s Opdivo (nivolumab) biosimilar candidate. 20 November 2024
Biotechnology
A pair of industry veterans have teamed up to create Jupiter Bioventures, a San Francisco-based biotech venture foundry promised to build bold, science-driven therapeutics companies. 20 November 2024
Biotechnology
The UK’s health technology assessor the Institute for Health and Clinical Excellence (NICE) says that talks with the makers of Enhertu have ended without agreement, meaning guidance that does not recommend Enhertu for advanced breast cancer will remain unchanged. 20 November 2024
Biotechnology
German biotech CatalYm has followed up a groundbreaking 2023 with an impressive 2024. 19 November 2024
Biotechnology
US pharma giant Merck & Co today announced positive top-line results from the pivotal Phase III MK-3475A-D77 trial for its mega blockbuster drug Keytruda (pembrolizumab) in subcutaneous form. 19 November 2024
Biotechnology
Privately-held US biotech Georgiamune has announced the appointment of Mark Avagliano as chief business officer (CBO). 19 November 2024
Biotechnology
Germany’s Lindis Biotech, a specialist in multi-specific antibody platforms, has announced an exclusive licensing agreement with Pharmanovia, for the commercialization of Korjuny (catumaxomab). 19 November 2024
Biotechnology
Californian oncology-focused biotech Avenzo Therapeutics has announced a pair of important updates. 19 November 2024
Biotechnology
The Johnson & Johnson subsidiary Janssen has presented new data from the Phase III ANDROMEDA study, which evaluated Darzalex Faspro (daratumumab and hyaluronidase-fihj) as a treatment for patients with light chain (AL) amyloidosis. 8 December 2020
Biotechnology
US cell therapy company Bellicum Pharmaceuticals closed 10% lower on Monday. 8 December 2020
Pharmaceutical
Public procurements of drugs in Russia for the first three quarters of the current year amounted to 464 billion roubles ($6.27 billion), which is 10% more than a year ago, according to a recent report, published by the local analytics agency DSM Group. 8 December 2020
Biotechnology
US biopharma TG Therapeutics has announced two data sets at the 62nd American Society of Hematology (ASH) Annual Meeting. 7 December 2020
Biotechnology
Gilead Sciences company Kite has announced results from the primary analysis of ZUMA-5, a Phase II study evaluating Yescarta (axicabtagene ciloleucel) in adults with relapsed/refractory indolent non-Hodgkin lymphoma (iNHL) after at least two prior lines of therapy. 7 December 2020
Biotechnology
US biotech Syros Pharmaceuticals has acquired SY-2101, a clinical-stage drug candidate formerly known as ORH-2014, from Orsenix. 7 December 2020
Biotechnology
Kite today announced follow-up results from the pivotal ZUMA-2 trial of Tecartus (brexucabtagene autoleucel, formerly KTE-X19) in adult patients with relapsed or refractory mantle cell lymphoma (MCL), at the 62nd ASH Annual Meeting and Exposition. 7 December 2020
Biotechnology
New data from the pivotal Phase III MURANO and CLL14 studies support the efficacy of fixed-duration, chemotherapy-free Venclexta/Venclyxto (venetoclax)-based combinations in certain people with chronic lymphocytic leukemia (CLL) and provide more evidence on the potential value of minimal residual disease (MRD). 7 December 2020
Pharmaceutical
COVID-19 vaccine news took center stage last week, with Wednesday seeing approval by the UK regulator of Pfizer and BioNTech’s BNT162b2, marking its first approval anywhere in the world. Last Monday Moderna released new data on its COVID-19 vaccine candidate mRNA-1273 and said it was filing for both US and European approval for emergency use. Also, US vaccine developer Novavax updated on the progress of its NVXCoV2373 COVID-19 vaccine program. Elsewhere, Jazz Pharmaceuticals and Spain’s PharmaMar released disappointing Phase III data for their lung cancer drug candidate Zepzelca. 6 December 2020
Pharmaceutical
Shares in the Spain’s PharmaMar plunged as much as 17% on Thursday after, along with US partner Jazz Pharmaceuticals, it released late-stage data for their lung cancer drug Zepzelca (lurbinectedin) which missed set goals. 4 December 2020
Biotechnology
The pharmaceutical arm of Johnson & Johnson has submitted to the US regulator for approval to market amivantamab in non-small cell lung cancer (NSCLC). 4 December 2020
Pharmaceutical
Shares of Australia’s Noxopharm closed down 10.16% at A$0.57 today, despite announcing encouraging news with its investigational drug Veyonda (idronoxil). 3 December 2020
Pharmaceutical
A new R&D collaboration between UK-headquartered Artios Pharma and Germany’s Merck KGaA will seek to discover and develop multiple precision oncology drugs. 3 December 2020
Biotechnology
The bladder cancer therapeutics market was valued at $670 million in 2018 across the seven major markets (7MM: USA, France, Germany, Italy, Spain, UK and Japan) and is expected to grow exponentially at a compound annual growth rate (CAGR) of 23.6% - accruing slightly less than $5.6 billion in 2028. 3 December 2020
Biotechnology
Genomics-based drug discovery company Exelixis has exercised its exclusive option for Iconic Therapeutics’ lead oncology antibody-drug conjugate (ADC) program under a May 2019 agreement that also involves Zymeworks. 2 December 2020
Pharmaceutical
US pharma major AbbVie and Frontier Medicines, a precision medicine company launched last year with a $67 million financing round, today announced a global strategic collaboration to discover, develop and commercialize a pipeline of innovative small molecule therapeutics against high-interest, difficult-to-drug protein targets. 2 December 2020
Biotechnology
British contract development and manufacturing organization (CDMO) Sterling Pharma Solutions has announced a new strategic partnership with ADC Biotechnology (ADC Bio), a UK based biotechnology company specializing in antibody drug conjugates. 2 December 2020
Biotechnology
Shares of USA-based Moleculin Biotech shot up more than 33% to $1.04 yesterday, after in revealed that the US Food and Drug Administration has approved its request for a Rare Pediatric Disease (RPD) designation for its drug candidate WP1066. 2 December 2020
Biotechnology
The US Food and Drug Administration yesterday approved Blueprint Medicines’ Gavreto (pralsetinib) for adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC). 2 December 2020
Biotechnology
California’s BridgeBio Pharma has announced that its affiliate QED Therapeutics has had its New Drug Application (NDA) accepted by the US Food and Drug Administration (FDA) for infigratinib, an oral FGFR1-3 selective inhibitor, for cholangiocarcinoma. 1 December 2020
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze